Investor Toolbox
Listen to Call
Recording not yet available.
Read Transcript
Transcript not yet available.
JNJ Coverage
Event
Johnson & Johnson (JNJ) Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)
Feb 24, 2026
Event
Johnson & Johnson (JNJ) RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer
Feb 19, 2026
Event
Johnson & Johnson (JNJ) Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania
Feb 18, 2026
Transcript
Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript
Jan 26, 2026
Transcript
Johnson & Johnson (JNJ) Q2 2025 Earnings Call Transcript
Jan 22, 2026
Transcript
Johnson & Johnson (JNJ) Q3 2025 Earnings Call Transcript
Jan 22, 2026
News
Infographic: How Johnson & Johnson (JNJ) performed in Q4 2025
Jan 21, 2026
Research
Johnson & Johnson: Healthcare Outlook
Jan 20, 2026